NLSPW - NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter | Benzinga
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) recently released a comprehensive shareholder letter by its CEO, Alex Zwyer, detailing recent achievements and ongoing endeavors. The letter, addressed to shareholders and friends, emphasizes NLS's commitment to improving patients' lives by advancing novel treatments for rare and complex CNS disorders.
Key Highlights:
1. Vision and Progress:
Zwyer acknowledges the dedication of the team at NLS in realizing their vision of enhancing patients' futures. The company emphasizes its mission to develop better therapies for rare sleep disorders and debilitating CNS diseases while putting patients first.
2. Objectives and Achievements:
At the beginning of 2023, NLS set out several goals, including building an organization focused on rare CNS disorders, advancing the Phase 3 program for lead product Mazindol ER, and progressing its pipeline of innovative products. The company highlights substantial progress in these areas.
3. Financing and Strategic Planning:
NLS completed a $10 million private placement in late 2022 with BVF Partners L.P. The ...